Safe to combine Sputnik V with other COVID-19 jabs, timely study suggests
Initial results show the immune response and safety of heterogeneous regimens combining the first component of the Russian Sputnik V vaccine (Sputnik Light vaccine based on human adenovirus serotype 26) and other COVID-19 jabs.
The Russian Direct Investment Fund (RDIF), a partner of the study, has announced the results of the trial, which saw Sputnik V combined with the vaccines from AstraZeneca (LSE: AZN), Sinopharm and Moderna (Nasdaq: MRNA).
"RDIF is ready to partner with other producers for further mix and match studies"The data, collected by the Ministry of Health of the Buenos Aires province in Argentina, demonstrates that both the combination of Sputnik Light with other vaccines and vaccination with two injections of only Sputnik Light shows high safety profile with no serious adverse events related to vaccination. All of the combinations studied were safe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze